Kiniksa Pharmaceuticals International, plc KNSA
As ofNov 20, 2026, 11:15 AM EST
- YTD
- +130.05%
- 1 year
- +128.72%
Fundamental scorecard
13 of 25 checks passed on KNSA’s reported financials
13of 25 checks passed
- Value 0 of 5
- Growth 4 of 5
- Profitability 4 of 5
- Financial health 5 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Value 0 of 5
- Failed:P/E below its own 5-year median P/E 67.9 against a 5-year median of 53.0.
- Failed:P/E under 20 P/E 67.9: an earnings yield of 1.5%.
- Failed:Price to sales below its own 5-year median Price to sales 7.9 against a 5-year median of 4.6.
- Failed:Price to book below its own 5-year median Price to book 10.5 against a 5-year median of 3.3.
- Failed:Free cash flow yield above 4% Free cash flow of 197M is 2.6% of the market value.
Growth 4 of 5
- Passed:Revenue grew over the last year Revenue of 946M is +58.2% on the 12 months before.
- No data:Revenue grew more than 5% a year over five years Not enough data to decide.
- Passed:Earnings per share grew over the last year EPS 1.31 against 0.45 in the 12 months before.
- Passed:Earnings per share grew more than 5% a year over five years EPS -2.61 in FY 2020, 0.75 in FY 2025.
- Passed:Analysts expect higher earnings per share over the next year The average forward estimate is +54.9% on the last 12 months.
Profitability 4 of 5
- Passed:Profitable over the last year Net income of 110M over the last 12 months.
- Failed:Profitable in each of the last five fiscal years A profit in 3 of the last 5 fiscal years.
- Passed:Return on equity above 15% Return on equity of 17.6%.
- Passed:Net margin above its 5-year average Net margin of 11.6% against a 5-year average of -64.5%.
- Passed:Free cash flow is at least 80% of net income Free cash flow of 197M is 180.0% of net income.
Financial health 5 of 5
- Passed:Short-term assets cover short-term liabilities Short-term assets of 750M against short-term liabilities of 192M.
- Passed:Short-term assets cover long-term liabilities Short-term assets of 750M against long-term liabilities of 81.2M.
- Passed:Net debt under 40% of equity More cash than debt: 569M of cash against 7.88M of debt.
- Passed:Operating cash flow covers at least 20% of debt Operating cash flow of 199M is 2522.0% of debt.
- Passed:Operating profit covers interest at least 3 times No interest expense reported.
Dividend 0 of 5
- Failed:Pays a dividend No dividend paid.
- Failed:Yield above 1.5% No dividend paid.
- Failed:Pays out under 75% of profit No dividend paid.
- Failed:Covered by free cash flow No dividend paid.
- Failed:Not cut in the last five fiscal years No dividend paid.
Mechanical checks on reported financials against fixed thresholds. They describe the numbers; they are not a recommendation to buy or sell.
Included in Essentials and up
Sign in to see Fair value
Discounted cash flow estimates against the price, and the P/E against its industry and sector.
Included in Essentials and up
Sign in to see Head count and owner earnings
Employees by annual report and the cash the business earns for its owners.
Included in Essentials and up
Sign in to see P/E against peers
The price to earnings ratio beside the closest competitors and their median.
Financial position
What KNSA owns and owes, as of Sep 30, 2026
Short term and long term
Balance sheet · 983M of assets
Debt, equity and cash by year
Now: 561M more cash than debt
Fiscal years, then the newest quarter. Cash includes short-term investments.
From the company’s SEC filings.
Included in Essentials and up
Sign in to see Cash flow and returns
How profit turns into free cash flow, and the returns on equity, assets and capital.
Financial health
Altman Z-Score
18.13 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
6 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
Rating
B3 / 5 overall
- DCF 1
- Return on Equity 4
- Return on Assets 5
- Debt / Equity 4
- P/E 1
- P/B 1
